Tauromustine was administered orally in weekly doses with interindivid
ual dose escalation to patients with disseminated malignant melanoma.
The dose in the first cohort of 6 patients was 20 mg/m2/week. The dose
escalation was 5 mg/m2/week. The limit of tolerance was 55 mg/m2/week
. 99 patients completed at least 8 weeks of treatment and eight dose l
evels were evaluated for toxicity. Reversible thrombocytopenia, and to
a lesser degree leukopenia, were dose limiting. From a starting dose
of 40 mg/m2/week, the long-term tolerated dose was 35 mg/m2/week, thus
achieving a considerable increase of dose intensity without a signifi
cant increase of toxicity by employing this weekly schedule of tauromu
stine.